At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ATOS Atossa Genetics
Post-Market Trading 11-25 18:04:19 EST
1.28
+0.06
+4.92%
盘后1.33
+0.05+3.88%
17:56 EST
High1.36Low1.25Vol1.14M
Open1.25D1 Closing1.22Amplitude9.02%
Mkt Cap161.03MTradable Cap151.00MTotal Shares125.80M
T/O1.50MT/O Rate0.97%Tradable Shares117.97M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Atossa Therapeutics announces five abstracts on Z-endoxifen
TIPRANKS  ·  11-20
Atossa Therapeutics announces five abstracts on Z-endoxifen
BRIEF-Atossa Therapeutics- Enters Open Market Sale Agreement To Sell Shares Of Common Stock Of Up To $100 Million From Time To Time - SEC Filing
Reuters  ·  11-20
BRIEF-Atossa Therapeutics- Enters Open Market Sale Agreement To Sell Shares Of Common Stock Of Up To $100 Million From Time To Time - SEC Filing
Atossa Therapeutics- Got Into Open Market Sale Agreement, May Offer & Sell Shares of Our Common Stock of up to $100 Mln From Time to Time - SEC Filing
THOMSON REUTERS  ·  11-20
Atossa Therapeutics- Got Into Open Market Sale Agreement, May Offer & Sell Shares of Our Common Stock of up to $100 Mln From Time to Time - SEC Filing
Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year?
Zacks  ·  11-18
Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year?
Atossa Therapeutics Q3 EPS $(0.06), Inline
Benzinga  ·  11-12
Atossa Therapeutics Q3 EPS $(0.06), Inline
Atossa Therapeutics Q3 Net Income USD -7.23 Million
THOMSON REUTERS  ·  11-12
Atossa Therapeutics Q3 Net Income USD -7.23 Million
Atossa Therapeutics Q3 Operating Income USD -6.385 Million
THOMSON REUTERS  ·  11-12
Atossa Therapeutics Q3 Operating Income USD -6.385 Million
Atossa Therapeutics Q3 Pretax Profit USD -7.23 Million
THOMSON REUTERS  ·  11-12
Atossa Therapeutics Q3 Pretax Profit USD -7.23 Million
Atossa Therapeutics: Important News, But The Company Still Has A Long Way To Go
seekingalpha  ·  11-09
Atossa Therapeutics: Important News, But The Company Still Has A Long Way To Go
Atossa Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview
Reuters  ·  11-08
Atossa Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  11-08
Calendar of U.S. Earnings Expected in the Week Ahead
Atossa Therapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
Dow Jones  ·  11-05
Atossa Therapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
Atossa Therapeutics Appoints Claudia Lopez, Dvm, MSC, as Vice President, Clinical Product Development
THOMSON REUTERS  ·  11-05
Atossa Therapeutics Appoints Claudia Lopez, Dvm, MSC, as Vice President, Clinical Product Development
Press Release: Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development
Dow Jones  ·  11-05
Press Release: Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development
Atossa Therapeutics - Low Doses of (Z)-Endoxifen Significantly Reduced Mbd and Was Generally Well Tolerated
THOMSON REUTERS  ·  11-04
Atossa Therapeutics - Low Doses of (Z)-Endoxifen Significantly Reduced Mbd and Was Generally Well Tolerated
Atossa Therapeutics Reports Positive Karisma-Endoxifen Trial Results:
THOMSON REUTERS  ·  11-04
Atossa Therapeutics Reports Positive Karisma-Endoxifen Trial Results:
Atossa preliminary analysis phase 2 trial of z-endoxifen met primary endpoint
TIPRANKS  ·  10-31
Atossa preliminary analysis phase 2 trial of z-endoxifen met primary endpoint
Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in Er+/Her2- Breast Cancer
THOMSON REUTERS  ·  10-31
Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in Er+/Her2- Breast Cancer
Atossa Therapeutics - Low Dose (Z)-Endoxifen Was Well Tolerated and Demonstrated Promising Rapid Activity in Reducing 3-WK Ki-67 and Ftv Biomarkers
THOMSON REUTERS  ·  10-31
Atossa Therapeutics - Low Dose (Z)-Endoxifen Was Well Tolerated and Demonstrated Promising Rapid Activity in Reducing 3-WK Ki-67 and Ftv Biomarkers
Atossa - (Z)-Endoxifen at 10 Mg Once Daily Met Primary Endpoint With 19/20 (95%) Receiving > 75 % of Planned Treatment in I-Spy-2 Phase 2 Trial
THOMSON REUTERS  ·  10-31
Atossa - (Z)-Endoxifen at 10 Mg Once Daily Met Primary Endpoint With 19/20 (95%) Receiving > 75 % of Planned Treatment in I-Spy-2 Phase 2 Trial

Introduction

Company Name.
Atossa Genetics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Issue price:
--